FGI-106 is a potent, broad-spectrum inhibitor demonstrating activity against various viruses, including Ebola, Rift Valley Fever, and Dengue Fever, exhibiting EC50 values of 100 nM, 800 nM, and 400-900 nM, respectively. Furthermore, it effectively inhibits non-hemorrhagic fever viruses such as HCV and HIV-1, with EC50s of 200 nM and 150 nM, respectively.

HCV: 200 nM , Rift Valley virus: 800 nM , DENV: 400-900 nM , HIV-1:150 nM , EBOV:（EC50）100 nM

In cell-based assays, FGI-106 effectively inhibits replication across diverse virus families, encompassing both positive and negative-strand RNA viruses. A concentration of 2 μM FGI-106 resulted in a significant four-log decrease in infectious viral titers compared to matched controls. Moreover, the effective concentration required to achieve 90% inhibition of viral-induced cytotoxicity in host cells (Vero E6 cells) is estimated to be 0.6 μM.

FGI-106 (0.1-5 mg/kg; intraperitoneal injection; treatments on days 2 and 5; C57BL/6 or BALB/c mice) reduces mortality from Zaire EBOV in a dose-dependent manner.